Multiply Labs raises $75 million to expand robotic manufacturing for cell therapies
Multiply Labs announced a $75 million Series B to scale robotic systems that automate manufacturing for individualized medicines, including cell therapies. The company’s approach uses modular robotic clusters intended to perform complex production steps with less manual intervention while preserving the parallel processing required for patient-specific treatments. The financing is designed to accelerate deployment and expand the organization as pharmaceutical companies seek more consistent and scalable ways to manufacture advanced therapies. For candidates, the round represents a substantial investment in the convergence of robotics, software, regulated manufacturing and life sciences. The company’s announcement confirms the capital and expansion objective, but it does not establish how quickly deployments will grow or disclose a detailed hiring breakdown. Execution will depend on validation, regulatory requirements, customer adoption and reliable performance in environments where quality failures can directly affect patients.
Read analysis ↗